NCT02401347View on ClinicalTrials.gov

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 23, 2019

Study Completion Date

December 31, 2022

Conditions
Advanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer
Interventions
DRUG

Talazoparib Tosylate

Participants receive Talazoparib tosylate at 1 mg by mouth daily.

Trial Locations (1)

94305

Stanford Medicine at Stanford University, Stanford

Sponsors
All Listed Sponsors
collaborator

BioMarin Pharmaceutical

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Melinda Telli

OTHER